TY - JOUR
T1 - Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles
AU - Duan, Jinghua
AU - Mansour, Heidi M.
AU - Zhang, Yangde
AU - Deng, Xingming
AU - Chen, Yuxiang
AU - Wang, Jiwei
AU - Pan, Yifeng
AU - Zhao, Jinfeng
N1 - Funding Information:
This study was supported by a Lotus Scholars Program ( 200734 ) in Hunan Province, PR China.
PY - 2012/4/15
Y1 - 2012/4/15
N2 - Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparticles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The mean particle size and mean zeta potential of CUR-DOX-PBCA-NPs were 133 ± 5.34 nm in diameter and +32.23 ± 4.56 mV, respectively. The entrapment efficiencies of doxorubicin and curcumin were 49.98 ± 3.32% and 94.52 ± 3.14%, respectively. Anticancer activities and reversal efficacy of the formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2- yl] 2,5-diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs (DOX-PBCA-NPs + CUR-PBCA-NPs), which was slightly higher than that of the free drug combination (DOX + CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX + CUR-PBCA-NPs or CUR + DOX-PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efficacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced by combination delivery of encapsulated cytotoxic drugs and reversal agents.
AB - Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparticles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The mean particle size and mean zeta potential of CUR-DOX-PBCA-NPs were 133 ± 5.34 nm in diameter and +32.23 ± 4.56 mV, respectively. The entrapment efficiencies of doxorubicin and curcumin were 49.98 ± 3.32% and 94.52 ± 3.14%, respectively. Anticancer activities and reversal efficacy of the formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2- yl] 2,5-diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs (DOX-PBCA-NPs + CUR-PBCA-NPs), which was slightly higher than that of the free drug combination (DOX + CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX + CUR-PBCA-NPs or CUR + DOX-PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efficacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced by combination delivery of encapsulated cytotoxic drugs and reversal agents.
KW - Curcumin
KW - Doxorubicin
KW - Multidrug resistance
KW - Poly(butyl cyanoacrylate) nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=84862808031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862808031&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2012.01.020
DO - 10.1016/j.ijpharm.2012.01.020
M3 - Article
C2 - 22274587
AN - SCOPUS:84862808031
VL - 426
SP - 193
EP - 201
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
SN - 0378-5173
IS - 1-2
ER -